Chicago, IL (PRWEB) June 21, 2013
The prescription drug safety center DrugRisk.com is announcing updates for patients taking the blood thinner Pradaxa. A new study from Denmark warns of a potential risk in switching to Pradaxa from other blood thinners*, as court records show patient lawsuits alleging bleeding continue to grow in the U.S.**.
DrugRisk’s goal is to improve patient safety by providing the latest warnings, recalls, studies and legal news for popular prescription drugs like Pradaxa. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts disagree, however, about whether it carries higher risks for internal bleeding. The FDA has advised that Pradaxa is no more dangerous than traditional blood thinner warfarin***.
However, the Institute for Safe Medication Practices warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from warfarin, and named anticoagulants like Pradaxa among the most dangerous drugs available****. A study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected*****.
Now, DrugRisk has learned that a new study from Denmark suggests many patients may be using Pradaxa improperly, and the risks of internal bleeding are heightened when switching from other blood thinners*.
A growing number of patients have filed a Pradaxa lawsuit alleging internal bleeding, leading cases to be consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. DrugRisk notes the latest court records show as many as 1,037 patients have filed a Pradaxa bleeding lawsuit**.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
*British Medical Journal, 5/3/13; bmjopen.bmj.com/content/3/5/e002758.long
**Judicial Panel on MultiDistrict Litigation 5/15/13; jpml.uscourts.gov/sites/jpml/files/Pending%20MDL%20Dockets_By%20District_May-14-2013.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834